A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
A phase 1/2 trial of MBS303 in non-Hodgkin lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
Overview
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL is a phase 1/2 interventional study registered as NCT05806099 by Beijing Mabworks Biotech Co., Ltd., with 132 participants planned, started 2023-06-28 and due to reach its primary completion in 2025-11. Interventions recorded: MBS303.
Similar pages
not linked directly; found by shared links- TrialA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Shares Beijing Mabworks Biotech and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.